ZA966148B - Novel formulation. - Google Patents
Novel formulation.Info
- Publication number
- ZA966148B ZA966148B ZA9606148A ZA966148A ZA966148B ZA 966148 B ZA966148 B ZA 966148B ZA 9606148 A ZA9606148 A ZA 9606148A ZA 966148 A ZA966148 A ZA 966148A ZA 966148 B ZA966148 B ZA 966148B
- Authority
- ZA
- South Africa
- Prior art keywords
- novel formulation
- formulation
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Polyurethanes Or Polyureas (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9514842.5A GB9514842D0 (en) | 1995-07-20 | 1995-07-20 | Novel formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA966148B true ZA966148B (en) | 1998-01-19 |
Family
ID=10777960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9606148A ZA966148B (en) | 1995-07-20 | 1996-07-19 | Novel formulation. |
Country Status (41)
Country | Link |
---|---|
EP (2) | EP0839039B2 (xx) |
JP (2) | JP3922392B2 (xx) |
KR (1) | KR100468351B1 (xx) |
CN (2) | CN1282456C (xx) |
AP (1) | AP1052A (xx) |
AR (1) | AR003463A1 (xx) |
AT (1) | ATE253361T1 (xx) |
AU (1) | AU6659196A (xx) |
BG (1) | BG64076B1 (xx) |
BR (1) | BR9609857A (xx) |
CA (2) | CA2227298C (xx) |
CY (1) | CY2408B1 (xx) |
CZ (1) | CZ294110B6 (xx) |
DE (1) | DE69630603T3 (xx) |
DK (1) | DK0839039T4 (xx) |
DZ (1) | DZ2074A1 (xx) |
EA (2) | EA003775B1 (xx) |
EG (1) | EG23934A (xx) |
ES (1) | ES2208757T5 (xx) |
GB (1) | GB9514842D0 (xx) |
HK (1) | HK1010494A1 (xx) |
HU (1) | HU228853B1 (xx) |
IL (1) | IL122940A0 (xx) |
MA (1) | MA23942A1 (xx) |
MX (1) | MX9800571A (xx) |
MY (1) | MY141373A (xx) |
NO (1) | NO315637B1 (xx) |
NZ (1) | NZ315006A (xx) |
OA (1) | OA10652A (xx) |
PE (1) | PE16098A1 (xx) |
PL (1) | PL184987B1 (xx) |
PT (1) | PT839039E (xx) |
RO (1) | RO119119B1 (xx) |
SI (1) | SI0839039T2 (xx) |
SK (1) | SK284117B6 (xx) |
TR (1) | TR199800077T1 (xx) |
TW (1) | TW464513B (xx) |
UA (1) | UA68328C2 (xx) |
UY (3) | UY24288A1 (xx) |
WO (1) | WO1997003670A1 (xx) |
ZA (1) | ZA966148B (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
KR100543614B1 (ko) | 1997-06-10 | 2006-01-20 | 신톤 비.브이. | 4-페닐피페리딘 화합물 |
US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
IL133080A0 (en) | 1997-07-01 | 2001-03-19 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
GB9808479D0 (en) * | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Method of treatment |
CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
CA2367402C (en) | 1999-03-12 | 2010-11-23 | Basf Aktiengesellschaft | Stable pharmaceutical dosage form for paroxetine anhydrate |
ES2290027T3 (es) * | 1999-05-20 | 2008-02-16 | Elan Corporation, Plc | Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina. |
IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
ES2159260B1 (es) * | 1999-06-22 | 2002-05-01 | Smithkline Beechan Plc | Nueva composicion de metanosulfonato de paroxetina |
AU5078700A (en) * | 1999-06-22 | 2001-01-09 | Smithkline Beecham Plc | Novel composition |
ES2162560B1 (es) * | 1999-06-25 | 2002-07-16 | Rodriguez Concepcion Pena | Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia. |
AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
WO2003013480A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
GB2392385A (en) * | 2002-09-02 | 2004-03-03 | Cipla Ltd | Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone |
CN1874767A (zh) | 2003-10-29 | 2006-12-06 | 惠氏公司 | 包含aplindore和其衍生物的缓释药物组合物 |
CA2556216A1 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
WO2005107716A1 (en) * | 2004-03-25 | 2005-11-17 | Cadila Healthcare Limited | Controlled release paroxetine-containing tablets based on a core and a coating |
AU2006274565B2 (en) * | 2005-08-02 | 2012-05-17 | Lupin Limited | Novel controlled release compositions of selective serotonin reuptake inhibitors |
KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
US20090130206A1 (en) * | 2006-05-09 | 2009-05-21 | Umesh Nandkumar Khatavkar | Controlled Release Compositions of an Antidepressant Agent |
KR100885029B1 (ko) | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
WO2009006299A2 (en) * | 2007-06-29 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Multi-particulate systems |
WO2009035652A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
TW201010743A (en) | 2008-09-05 | 2010-03-16 | Otsuka Pharma Co Ltd | Pharmaceutical solid preparation |
MX2012002199A (es) * | 2009-08-24 | 2012-03-16 | Lundbeck & Co As H | Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina. |
CN103371982A (zh) * | 2012-04-20 | 2013-10-30 | 王进京 | 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法 |
WO2014009152A1 (en) * | 2012-07-09 | 2014-01-16 | Unilever N.V. | A photoprotective personal care composition |
CN103550182B (zh) * | 2013-10-29 | 2015-04-08 | 吉林省东盟制药有限公司 | 一种肠溶缓释组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
MC2025A1 (fr) * | 1988-04-20 | 1990-04-25 | Asta Pharma Ag | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee |
IT1237904B (it) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
JPH0436237A (ja) * | 1990-06-01 | 1992-02-06 | Taiho Yakuhin Kogyo Kk | 抗腫瘍性複合製剤 |
JP3064417B2 (ja) * | 1990-08-21 | 2000-07-12 | セラテック,インコーポレイテッド | 放出制御性製剤及び方法 |
WO1992009281A2 (en) * | 1990-11-24 | 1992-06-11 | Beecham Group Plc | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
EP0720478A1 (en) * | 1991-05-07 | 1996-07-10 | Dynagen, Inc. | A controlled, sustained release delivery system for smoking cessation |
JPH05139964A (ja) * | 1991-11-14 | 1993-06-08 | Takada Seiyaku Kk | 塩酸メキシレチン腸溶性製剤 |
EP0654263B1 (en) * | 1993-11-23 | 2002-01-23 | Euro-Celtique S.A. | Method for preparing a sustained release composition |
IT1274241B (it) * | 1993-12-03 | 1997-07-15 | Smithkline Beecham Farma | Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono |
CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
EP0818990A1 (en) * | 1995-04-03 | 1998-01-21 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
-
1995
- 1995-07-20 GB GBGB9514842.5A patent/GB9514842D0/en active Pending
-
1996
- 1996-07-17 DZ DZ960118A patent/DZ2074A1/fr active
- 1996-07-18 MY MYPI96002956A patent/MY141373A/en unknown
- 1996-07-18 MA MA24317A patent/MA23942A1/fr unknown
- 1996-07-18 EG EG68296A patent/EG23934A/xx active
- 1996-07-18 AR ARP960103639A patent/AR003463A1/es not_active Application Discontinuation
- 1996-07-19 ZA ZA9606148A patent/ZA966148B/xx unknown
- 1996-07-19 WO PCT/EP1996/003252 patent/WO1997003670A1/en active IP Right Grant
- 1996-07-19 EA EA199800140A patent/EA003775B1/ru not_active IP Right Cessation
- 1996-07-19 MX MX9800571A patent/MX9800571A/es active IP Right Grant
- 1996-07-19 NZ NZ315006A patent/NZ315006A/xx not_active IP Right Cessation
- 1996-07-19 BR BR9609857A patent/BR9609857A/pt not_active Application Discontinuation
- 1996-07-19 SI SI9630661T patent/SI0839039T2/sl unknown
- 1996-07-19 EP EP96926388A patent/EP0839039B2/en not_active Expired - Lifetime
- 1996-07-19 PT PT96926388T patent/PT839039E/pt unknown
- 1996-07-19 EA EA200100022A patent/EA003508B1/ru not_active IP Right Cessation
- 1996-07-19 JP JP50632597A patent/JP3922392B2/ja not_active Expired - Lifetime
- 1996-07-19 CN CNB031490468A patent/CN1282456C/zh not_active Expired - Lifetime
- 1996-07-19 PL PL96324553A patent/PL184987B1/pl unknown
- 1996-07-19 UA UA98010283A patent/UA68328C2/uk unknown
- 1996-07-19 TW TW085108758A patent/TW464513B/zh not_active IP Right Cessation
- 1996-07-19 HU HU9900299A patent/HU228853B1/hu unknown
- 1996-07-19 DK DK96926388T patent/DK0839039T4/da active
- 1996-07-19 CN CN96196819A patent/CN1117567C/zh not_active Expired - Lifetime
- 1996-07-19 PE PE1996000548A patent/PE16098A1/es not_active IP Right Cessation
- 1996-07-19 UY UY24288A patent/UY24288A1/es not_active IP Right Cessation
- 1996-07-19 DE DE69630603T patent/DE69630603T3/de not_active Expired - Lifetime
- 1996-07-19 AU AU66591/96A patent/AU6659196A/en not_active Abandoned
- 1996-07-19 EP EP03078259A patent/EP1382337A1/en not_active Withdrawn
- 1996-07-19 CZ CZ1998183A patent/CZ294110B6/cs not_active IP Right Cessation
- 1996-07-19 TR TR1998/00077T patent/TR199800077T1/xx unknown
- 1996-07-19 CA CA002227298A patent/CA2227298C/en not_active Expired - Lifetime
- 1996-07-19 KR KR10-1998-0700380A patent/KR100468351B1/ko not_active IP Right Cessation
- 1996-07-19 SK SK53-98A patent/SK284117B6/sk not_active IP Right Cessation
- 1996-07-19 CA CA002445678A patent/CA2445678C/en not_active Expired - Lifetime
- 1996-07-19 RO RO98-00082A patent/RO119119B1/ro unknown
- 1996-07-19 AP APAP/P/1998/001177A patent/AP1052A/en active
- 1996-07-19 ES ES96926388T patent/ES2208757T5/es not_active Expired - Lifetime
- 1996-07-19 IL IL12294096A patent/IL122940A0/xx not_active IP Right Cessation
- 1996-07-19 AT AT96926388T patent/ATE253361T1/de active
-
1997
- 1997-01-10 UY UY24436A patent/UY24436A1/es not_active IP Right Cessation
-
1998
- 1998-01-19 NO NO19980240A patent/NO315637B1/no not_active IP Right Cessation
- 1998-01-20 OA OA9800005A patent/OA10652A/en unknown
- 1998-02-17 BG BG102259A patent/BG64076B1/bg unknown
- 1998-11-06 HK HK98111807A patent/HK1010494A1/xx not_active IP Right Cessation
-
2000
- 2000-07-13 UY UY26242A patent/UY26242A1/es not_active Application Discontinuation
-
2004
- 2004-03-15 CY CY0400019A patent/CY2408B1/xx unknown
-
2006
- 2006-04-27 JP JP2006123731A patent/JP2006265258A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA966148B (en) | Novel formulation. | |
ZA967084B (en) | Cement formulation. | |
ZA967315B (en) | Biphenylamides. | |
ZA962338B (en) | Oral 2-methyl-thieno-benzodiazepine formulation. | |
ZA9610858B (en) | Heteroclyclic compounds. | |
ZA965190B (en) | Pharmaceutical composition. | |
MX213417B (es) | Fenilpiridazinonas. | |
EP0634459A3 (de) | Formulierungen. | |
ZA967034B (en) | Pharmaceutical compositions. | |
ZA966075B (en) | Protein formulation. | |
ZA968250B (en) | Cosmetic composition. | |
ZA964433B (en) | Cosmetic composition. | |
ZA964468B (en) | Triazolylmethyl-cyclopentanols. | |
ZA965505B (en) | Novel compounds. | |
ZA967546B (en) | Pharmaceutical formulation. | |
ZA961955B (en) | Indazolecarboxamides. | |
ZA967420B (en) | Hand cleanser. | |
ZA964872B (en) | Sunscreen compositions. | |
DE69610844D1 (en) | Hydroformylierungsverfahren. | |
ZA968081B (en) | Pharmaceutical composition. | |
ZA96796B (en) | Transdermal formulation. | |
PL326837A1 (en) | 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles | |
ZA966399B (en) | Endothelin-receptor-antagonists. | |
ZA964560B (en) | Anit-viral compounds. | |
ZA966933B (en) | Endothelin-receptor-antagonists. |